世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

mRNAワクチン市場-世界の産業規模、シェア、動向、機会、および予測、2018年-2028年mRNAタイプ別(ヌクレオシド修飾mRNA、非修飾mRNA、自己増幅mRNA)、用途別(COVID-19 mRNAワクチン、非COVID-19 mRNAワクチン、その他)、地域別および競合別に分類


mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028Segmented By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA), By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others), Region and Competition

mRNAワクチンの世界市場は、生産、安全性、有効性、流通などの面で、DNAワクチンよりもmRNAワクチンの方が様々な利点があることから、予測期間中に目覚ましい成長を遂げる見通しです。mRNAワクチンの世界市場は、... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年8月1日 US$4,900
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
112 英語

 

サマリー

mRNAワクチンの世界市場は、生産、安全性、有効性、流通などの面で、DNAワクチンよりもmRNAワクチンの方が様々な利点があることから、予測期間中に目覚ましい成長を遂げる見通しです。mRNAワクチンの世界市場は、癌、遺伝子異常、ウイルス感染などの発生率の上昇によって牽引されています。2020年には、死亡者数の約6人に1人にあたる約1,000万人ががんで死亡し、世界的に死因の上位を占める。TAA(腫瘍関連抗原)、TSA(腫瘍特異的抗原)、およびそれらに関連するサイトカインはすべて、mRNAワクチンによってコード化・発現させることができ、がんワクチンの重要なクラスを構成している。mRNAがんワクチンは体液性免疫と細胞性免疫の両方を高めることができるため、これらのワクチンは様々な疾患や患者に適応しやすい。その上、COVID-19パンデミックの突然の発生と広がり、COVID-19に対するModernaとPfizer- BioNTechのワクチンの成功は、今後数年間、mRNAワクチン市場の成長に新たな展望を生み出すと期待されている。その結果、多くのバイオテクノロジー・製薬企業や学術・研究機関が名乗りを上げ、研究開発を開始し、さまざまな種類のmRNAワクチンの開発のための臨床試験を開始するようになり、予測期間中の世界のmRNAワクチン市場の成長に有利な機会を生み出しています。clinicaltrials.govによると、mRNAワクチンに関する444件の臨床研究が、世界のさまざまな地域でさまざまな開発段階にあります。
mRNAワクチンの広範な研究と展開が奨励される重要な理由は、その数々の際立った利点にある。mRNAワクチン開発の主な原因のひとつは、その製造の簡便さである。単純な形をしており、その活性成分であるRNAは多くの場合、直鎖DNAを鋳型としてin vitroで生産される。コドンの最適化、ヌクレオシドの修飾、デリバリー方法の追加などにより、この過程でmRNAの安定性と翻訳効率を高め、高い特異性と弾力性のある安定性を持つ核酸ワクチンを作り出すことができる。ワクチンの安全性は、普及を促すもう一つの重要な側面である。mRNAは宿主ゲノムに組み込まれないため、感染や遺伝的損傷の潜在的リスクはない。
mRNAワクチンは、人体に免疫反応を起こさせるタンパク質を作り出す。これらのワクチンは生きたウイルスを含まないため、接種後に発病する危険性はまったくない。身体はmRNAを速やかに分解し、細胞は外来のmRNAを容易に取り込まない。最近の技術進歩により、mRNA分子の安定性が向上し、細胞への送達効果を高めるために分子を脂質で包むようになった。これらの開発により、細胞内でのスパイクタンパク質の産生が促進され、より強力な免疫学的反応が引き起こされる。
さらに、翻訳、安定性、送達方法の強化における最近の技術開発により、メッセンジャーRNAは有望な治療ツールとして台頭してきた。実際、mRNAワクチンは新たな薬理学分野への扉を開き、重要な治療クラスとなっている。次世代ワクチン接種を支えるこれらのmRNAワクチンにより、ワクチン開発は新たな時代を迎えつつある。
業界の拡大は、最先端かつ効率的なmRNAワクチンの開発への投資の増加によって、予測期間中に支えられると予想される。例えば、米国のmRNA治療開発企業Arcturus Therapeuticsは、2021年4月にAxcelead, Inc.との合弁事業の一環として千葉県に日本法人を設立し、現在福島県南相馬市に生産工場を建設中である。今後数年間は、このような投資が市場拡大を補完することになるだろう。
mRNAワクチンの利点
mRNAワクチンの製造は、細胞培養を必要としないため、一般的なワクチンの製造と比較した場合、他の方法よりも利点がある。反応速度が速いため、他の高度なワクチン製造技術に見られるような汚染のリスクは小さい。さらに、mRNAワクチンは非集積性で細胞内で一過性に発現するため、より安全である。配列が最適化されたmRNAを脂質でカプセル化したものや裸の状態で使用するmRNAワクチンは、特に近年、インフルエンザウイルス、ジカウイルス、狂犬病ウイルスなどの動物モデルにおいて、感染症標的に対する強力な免疫を生み出している。

mRNAベースのワクチン製造に向けた研究活動の活発化
より高い生物学的有効性、増強された強力な免疫原性、低毒性レベルでの汎用性の高いデリバリー・プラットフォームなど、mRNAが他の治療法と比べて提供する数多くの利点が、この分野で現在行われている研究開発の主な推進力となっている。糖尿病、HIV、癌、心血管疾患などの感染症や慢性疾患の予防を目的としたmRNAベースのワクチンの開発は、広範な研究の対象となっている。現在、COVID-19以外の疾患を予防するmRNAワクチンを用いた臨床試験が430件行われている。Clinicaltrials.govの分析によれば、これらの臨床試験の大半は米国で実施されている。
ペンシルバニア大学ペレルマン医学部の研究者たちによって、既知の20種類すべてのインフルエンザウイルス亜型を予防する、多価のmRNAベースのワクチンが作られた。研究者たちは、亜型に共通する抗原を少なくするのではなく、それぞれの亜型に特有の抗原を含めることによって、万能インフルエンザ・ワクチンを作ろうとした以前の試みとは異なるアプローチをとっている。ファイザーとモデナが製造したSARS-CoV-2ワクチンは、この戦略と同じmRNA技術を使用している。ペンは、これらのCOVID-19ワクチンに使用されたmRNA技術の開発におけるリーダーであった。

市場セグメンテーション
mRNAワクチンの世界市場は、mRNAのタイプ別、用途別、地域別に区分することができる。mRNAタイプに基づくと、市場はヌクレオシド修飾mRNA、非修飾mRNA、自己増幅mRNAに分けられる。用途に基づくと、市場はCOVID-19 mRNAワクチン、非COVID-19 mRNAワクチン、その他に分けられます。地域別では、mRNAワクチンは北米、欧州、アジア太平洋、南米、中東・アフリカに分類されます。

市場プレイヤー
Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd., Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc.などは、世界のmRNAワクチン市場で事業を展開する大手企業です。

レポートの範囲
本レポートでは、mRNAワクチンの世界市場を、業界動向に加えて以下のカテゴリーに分類しています:
- mRNAワクチンの世界市場:mRNAタイプ別
o ヌクレオシド修飾mRNA
o 非修飾mRNA
o 自己増幅型mRNA

- mRNAワクチンの世界市場:用途別
o COVID-19 mRNAワクチン
o 非COVID-19 mRNAワクチン
o その他
競合状況
企業プロフィール:mRNAワクチンの世界市場における主要企業の詳細分析
利用可能なカスタマイズ:
TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。このレポートでは以下のカスタマイズが可能です:
企業情報
- 追加市場参入企業(最大5社)の詳細分析とプロファイリング

ページTOPに戻る


目次

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Clinical Trial Analysis
4.1. Ongoing Clinical Trials
4.2. Completed Clinical Trials
4.3. Terminated Clinical Trials
4.4. Breakdown of Pipeline, By Development Phase
4.5. Breakdown of Pipeline, By Status
4.6. Breakdown of Pipeline, By Study Type
4.7. Breakdown of Pipeline, By Region
4.8. Clinical Trials Heat Map
5. Voice of Customer
6. Global mRNA Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
6.2.4. By Company (2022)
6.3. Product Map
6.3.1. By mRNA Type
6.3.2. By Application
6.3.3. By Region
7. North America mRNA Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States mRNA Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By mRNA Type
7.3.1.2.2. By Application
7.3.2. Canada mRNA Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By mRNA Type
7.3.2.2.2. By Application
7.3.3. Mexico mRNA Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By mRNA Type
7.3.3.2.2. By Application
8. Europe mRNA Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France mRNA Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By mRNA Type
8.3.1.2.2. By Application
8.3.2. Germany mRNA Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By mRNA Type
8.3.2.2.2. By Application
8.3.3. United Kingdom mRNA Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By mRNA Type
8.3.3.2.2. By Application
8.3.4. Italy mRNA Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By mRNA Type
8.3.4.2.2. By Application
8.3.5. Spain mRNA Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By mRNA Type
8.3.5.2.2. By Application
9. Asia-Pacific mRNA Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China mRNA Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By mRNA Type
9.3.1.2.2. By Application
9.3.2. India mRNA Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By mRNA Type
9.3.2.2.2. By Application
9.3.3. Japan mRNA Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By mRNA Type
9.3.3.2.2. By Application
9.3.4. South Korea mRNA Vaccine Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By mRNA Type
9.3.4.2.2. By Application
9.3.5. Australia mRNA Vaccine Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By mRNA Type
9.3.5.2.2. By Application
10. South America mRNA Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil mRNA Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By mRNA Type
10.3.1.2.2. By Application
10.3.2. Argentina mRNA Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By mRNA Type
10.3.2.2.2. By Application
10.3.3. Colombia mRNA Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By mRNA Type
10.3.3.2.2. By Application
11. Middle East and Africa mRNA Vaccine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa mRNA Vaccine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By mRNA Type
11.3.1.2.2. By Application
11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By mRNA Type
11.3.2.2.2. By Application
11.3.3. UAE mRNA Vaccine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By mRNA Type
11.3.3.2.2. By Application
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Merger Acquisition
13.3. Product launches
14. Global mRNA Vaccine Market: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
16.6.1. Arcturus Therapeutics Holdings Inc.
16.6.2. BioNTech SE
16.6.3. CureVac N.V.
16.6.4. Daiichi Sankyo Company Limited.
16.6.5. Ethris GmbH
16.6.6. GlaxoSmithKline plc
16.6.7. Gennova Biopharmaceuticals Ltd
16.6.8. Moderna, Inc.
16.6.9. Pantherna Therapeutics GmbH
16.6.10. Providence Therapeutics
16.6.11. Silence Therapeutics
16.6.12. Translate Bio
16.6.13. VERSAMEB AG
16.6.14. Verve Therapeutics Inc.
17. Strategic Recommendations

 

ページTOPに戻る


 

Summary

Global mRNA vaccine market is poised to grow at an impressive rate during the forecast period on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others. Global mRNA Vaccine Market is driven by the rising incidence of cancer, genetic abnormalities, and viral infections. Approximately 10 million deaths, or nearly one in six deaths, happened due to cancer in 2020, making it one of the top causes of death globally. TAA (tumor-associated antigens), TSA (tumor-specific antigens), and their related cytokines can all be encoded and expressed by mRNA vaccines, which constitute a significant class of cancer vaccines. These vaccines are more adaptable to various diseases and patients because mRNA cancer vaccines can boost both humoral and cellular immunity. Besides, the sudden outbreak and spread of the COVID-19 pandemic and the success of Moderna's and Pfizer- BioNTech's vaccines against COVID-19 are expected to create new prospects for growth of the mRNA vaccine market in the coming years. This has, in turn, resulted in many biotechnology & pharmaceutical companies and academic & research institutions coming forward and starting research and development and launching clinical trials for the development of different types of mRNA vaccines, thereby creating lucrative opportunities for the growth of global mRNA vaccine market during the forecast period. According to clinicaltrials.gov, around 444 clinical studies related to mRNA Vaccines are in different phases of development being conducted across different parts of the globe.
The important reason for encouraging extensive study and deployment of mRNA vaccines is their numerous distinctive benefits. One of the main causes for the development of mRNA vaccines is their convenience of production. Simple in form, its active component, RNA, is often produced in vitro utilizing linear DNA as a template. Through codon optimization, nucleoside modification, and an additional delivery method, the stability and translation efficiency of mRNA can be enhanced during this process to create a nucleic acid vaccine with high specificity and resilient stability. The vaccine's safety is another important aspect that encourages widespread use. There is no potential risk of infection or genetic damage because the mRNA does not integrate into the host genome.
mRNA vaccines create proteins that cause human bodies to generate an immune response. Since these vaccines don't involve live viruses, there is absolutely no risk of getting sick after receiving them. The body quickly breaks down mRNA, and cells don't readily take up foreign mRNA. Recent technological advancements have improved the stability of the mRNA molecule and wrapped the molecules in lipids to improve cell delivery effectiveness. These developments boost the production of spike protein in your cells, triggering a stronger immunological response.
Furthermore, owing to recent technological developments in enhanced translation, stability, and delivery methods, messenger RNAs have emerged as a promising therapeutic tool. In fact, mRNA vaccines have opened the door to new pharmacological fields and have become a significant therapeutic class. The development of vaccines is entering a new age because of these mRNA vaccines, which support next-generation vaccinations.
Industry expansion is anticipated to be supported during the projected time by increased investments in the development of cutting-edge and efficient mRNA vaccines. For instance, American mRNA therapeutic developer Arcturus Therapeutics established a Japanese company in Chiba Prefecture in April 2021 as part of a joint venture with Axcelead, Inc., and is currently building a production plant in Minamisoma City, Fukushima Prefecture. In the upcoming years, such investments are probably going to supplement market expansion.
Advantages of mRNA Vaccines
mRNA vaccine production has advantages over the other counterparts, when compared to the production of most vaccines, since it does not require the use of cell cultures. The risk of contamination is smaller than what is seen with other sophisticated vaccine manufacturing techniques because of its quick reaction time. Additionally, mRNA vaccines are safer due to their non-integrative nature and transitory expression within cells. Using lipid-encapsulated or naked forms of sequence-optimized mRNA, mRNA vaccines have produced potent immunity against infectious disease targets in animal models of influenza virus, Zika virus, rabies virus, and others, particularly in recent years.

Increasing Research Activities to produce mRNA-based Vaccines
The numerous benefits mRNA offers over other therapeutic modalities, such as higher biological efficacy, enhanced potent immunogenicity, and versatile delivery platforms at low toxicity levels, are the main drivers of the ongoing research and development efforts being made in this field. The development of mRNA-based vaccines to prevent infectious or chronic diseases like diabetes, HIV, cancer, and cardiovascular diseases is the subject of extensive research. There are currently 430 clinical trials using mRNA vaccines to prevent diseases other than COVID-19. The majority of these clinical trials, according to an analysis by Clinicaltrials.gov, are conducted in the United States.
A multivalent, mRNA-based vaccine that protects against all 20 known influenza virus subtypes has been created by researchers at the Perelman School of Medicine at the University of Pennsylvania. They take a different approach from earlier attempts to create a universal flu vaccine by including antigens unique to each subtype rather than just a smaller set of antigens shared by subtypes. The SARS-CoV-2 vaccines made by Pfizer and Moderna used the same mRNA technology as this strategy. Penn was a leader in the development of the mRNA technology used in those COVID-19 vaccines.

Market Segmentation
Global mRNA Vaccine Market can be segmented by mRNA type, by application, and by region. Based on mRNA type, the market can be divided into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA. Based on application the market is divided into COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, and others. Regionally, the mRNA Vaccine can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players
Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc., are some of the leading players operating in the Global mRNA Vaccine Market.

Report Scope:
In this report, Global mRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Global mRNA Vaccine Market, By mRNA Type:
o Nucleoside-modified mRNA
o Unmodified mRNA
o Self-Amplifying mRNA

• Global mRNA Vaccine Market, By Application:
o COVID-19 mRNA Vaccines
o Non COVID-19 mRNA Vaccines
o Others
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Global mRNA Vaccine Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).



ページTOPに戻る


Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Clinical Trial Analysis
4.1. Ongoing Clinical Trials
4.2. Completed Clinical Trials
4.3. Terminated Clinical Trials
4.4. Breakdown of Pipeline, By Development Phase
4.5. Breakdown of Pipeline, By Status
4.6. Breakdown of Pipeline, By Study Type
4.7. Breakdown of Pipeline, By Region
4.8. Clinical Trials Heat Map
5. Voice of Customer
6. Global mRNA Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
6.2.4. By Company (2022)
6.3. Product Map
6.3.1. By mRNA Type
6.3.2. By Application
6.3.3. By Region
7. North America mRNA Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States mRNA Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By mRNA Type
7.3.1.2.2. By Application
7.3.2. Canada mRNA Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By mRNA Type
7.3.2.2.2. By Application
7.3.3. Mexico mRNA Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By mRNA Type
7.3.3.2.2. By Application
8. Europe mRNA Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France mRNA Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By mRNA Type
8.3.1.2.2. By Application
8.3.2. Germany mRNA Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By mRNA Type
8.3.2.2.2. By Application
8.3.3. United Kingdom mRNA Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By mRNA Type
8.3.3.2.2. By Application
8.3.4. Italy mRNA Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By mRNA Type
8.3.4.2.2. By Application
8.3.5. Spain mRNA Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By mRNA Type
8.3.5.2.2. By Application
9. Asia-Pacific mRNA Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China mRNA Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By mRNA Type
9.3.1.2.2. By Application
9.3.2. India mRNA Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By mRNA Type
9.3.2.2.2. By Application
9.3.3. Japan mRNA Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By mRNA Type
9.3.3.2.2. By Application
9.3.4. South Korea mRNA Vaccine Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By mRNA Type
9.3.4.2.2. By Application
9.3.5. Australia mRNA Vaccine Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By mRNA Type
9.3.5.2.2. By Application
10. South America mRNA Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil mRNA Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By mRNA Type
10.3.1.2.2. By Application
10.3.2. Argentina mRNA Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By mRNA Type
10.3.2.2.2. By Application
10.3.3. Colombia mRNA Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By mRNA Type
10.3.3.2.2. By Application
11. Middle East and Africa mRNA Vaccine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa mRNA Vaccine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By mRNA Type
11.3.1.2.2. By Application
11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By mRNA Type
11.3.2.2.2. By Application
11.3.3. UAE mRNA Vaccine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By mRNA Type
11.3.3.2.2. By Application
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Merger Acquisition
13.3. Product launches
14. Global mRNA Vaccine Market: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
16.6.1. Arcturus Therapeutics Holdings Inc.
16.6.2. BioNTech SE
16.6.3. CureVac N.V.
16.6.4. Daiichi Sankyo Company Limited.
16.6.5. Ethris GmbH
16.6.6. GlaxoSmithKline plc
16.6.7. Gennova Biopharmaceuticals Ltd
16.6.8. Moderna, Inc.
16.6.9. Pantherna Therapeutics GmbH
16.6.10. Providence Therapeutics
16.6.11. Silence Therapeutics
16.6.12. Translate Bio
16.6.13. VERSAMEB AG
16.6.14. Verve Therapeutics Inc.
17. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

TechSci Research 社の最新刊レポート

本レポートと同じKEY WORD(mrna vaccines)の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/23 10:28

157.74 円

172.13 円

206.60 円

ページTOPに戻る